Let’s talk ↗
Menu
Our expertiseM&ANXD Family OfficePartnersResource CentreAbout usContact
← Resource Centre
M&A / Business exits / Competition

The highest offer is only part of a successful exit

A US challenge to a US$3.5bn veterinary distribution deal illustrates why founders should assess clearance risk, timing and business continuity alongside price.

An attractive offer can change a founder's plans overnight. It can bring retirement closer, provide capital for a new venture or give a management team confidence about its next chapter. Yet an agreed price is only one part of an exit. The route to completion deserves equally serious attention.

On 13 November, the US Federal Trade Commission sued to block Covetrus and its owners from acquiring MWI Veterinary Supply from Cencora for US$3.5 billion. The FTC alleges that the proposed transaction would combine the two largest suppliers in veterinary clinic distribution and distribution to large corporate accounts, harming competition. These are the regulator's allegations, not findings established by a court. [1]

Covetrus disputes the case. In its statement that day, it argued that veterinary practices have extensive purchasing alternatives through manufacturers, distributors and online marketplaces. It said it was prepared to defend the transaction in court. Those are the company's arguments, rather than independently proven benefits. [2]

Reuters reported both the challenge and the response on 13 November. The FTC's case register lists the matter as pending. A lawsuit seeking to block a deal is neither a completed acquisition nor a final prohibition. [3][4]

Understand the customer's alternatives

The disagreement illustrates an important commercial question: which suppliers can customers realistically use instead?

A buyer may see technology, distribution reach and efficiencies. A regulator may examine the rivalry between the businesses, how customers negotiate and whether alternative suppliers provide a comparable service. Our assessment is that this makes customer-level evidence essential to transaction preparation.

For a founder considering a sale to a competitor, start the discussion before accepting exclusivity. Ask specialist competition counsel to examine overlapping products, geography, customer groups and supply relationships. Broad market labels can conceal a much narrower area in which the two businesses regularly compete.

The US case does not establish how a UK transaction would be assessed. Different jurisdictions apply their own rules and procedures.

Put the timetable into the commercial plan

The Competition and Markets Authority explains that the UK merger regime is voluntary, while retaining the ability to investigate qualifying transactions on its own initiative. Its guidance also separates pre-notification information gathering from the formal phase 1 investigation. The latter has a 40-working-day legal deadline; an in-depth phase 2 review normally has a 24-week deadline, with an extension possible in special circumstances. [5]

Those stages should not be reduced to a promise that a sale will complete within a fixed number of weeks. Advisers need to assess the relevant jurisdictions, information requirements and possible paths through review.

Translate that assessment into a business plan. What happens to working capital, recruitment and customer renewals if completion moves back? Who carries additional advisory costs? How long is financing available? Which decisions can management take while the transaction remains conditional?

Compare the quality of offers

Ask advisers to compare price alongside completion conditions, funding evidence, the proposed timetable and the allocation of regulatory risk. A lower offer may or may not be preferable; the point is to make the trade-offs visible.

Discuss what happens if clearance requires a change to the business being sold. A disposal or other remedy could alter the commercial rationale. Agree how such possibilities will be handled rather than assuming the original economics survive every outcome.

Maintain a credible standalone plan throughout. Employees and customers still need a well-run business while an application, investigation or dispute proceeds. Planning for delay helps protect the value that attracted the buyer in the first place.

Chris McDonald’s perspective

I would encourage founders to ask two questions together: what is the business worth, and what has to happen for that value to reach the shareholders?

The headline offer matters. Understanding the conditions, responsibilities and alternatives gives you a stronger basis for choosing a buyer and managing the period before completion.

Sources & further reading

  1. Federal Trade Commission: FTC Sues to Block Veterinary Supplies Distributor Covetrus's $3.5 Billion Acquisition of Rival MWI ↗Published 13 November 2026
  2. Covetrus: Covetrus Issues Statement on FTC Decision to Challenge Proposed Merger with MWI Animal Health ↗Published 13 November 2026
  3. Reuters: US FTC sues to block Cencora's $3.5 billion sale of veterinary unit to Covetrus ↗Published 13 November 2026
  4. FTC: CVET Topco/MWI Veterinary Supply ↗Published 13 November 2026
  5. Competition and Markets Authority: Mergers: how they are investigated ↗Published 23 June 2025
Explore the Resource Centre ↗
NEWS & INSIGHTS

Keep up to date with the Team.

To keep up to date with new developments and articles from the Team, please provide your details here.

You can unsubscribe at any time using our online unsubscribe form or by emailing chris.mcdonald@nxdteam.com.